// App-Quantinova.ai

TPS7057 : BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53WT relapsed/refractory (R/R) myelofibrosis (MF).

Researchers

Presenter

  • Srdan Verstovsek

Principal Investigators

  • Haifa Kathrin Al-Ali

  • John Mascarenhas

  • Adam J. Mead

  • Andrew Perkins

  • Alessandro M. Vannucchi

  • Anne Uyei

  • Wayne P. Rothbaum

  • Jesse McGreivy

  • Jean-Jacques Kiladjian

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Krukenberg Cancer Center, University Hospital Halle,Halle,Deutschland

  • Icahn School of Medicine at Mount Sinai, New York, NY, University of Oxford, Oxford, United Kingdom

  • Australian Centre For Blood Diseases, Monash University, Melbourne, Australia

  • University of Florence, Florence, Italy

  • Kartos Therapeutics, Inc., Redwood City, CA

  • Hospital Saint Antoine, Paris, France

Locations

  • Germany

  • United Kingdom

  • Australia

  • Italy

  • France

Companies

  • Kartos Therapeutics,

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Essential thrombocythemia

  • Polycythemia vera

  • Myelofibrosis

Biomarkers

  • Mouse double minute 2 homolog

  • p53

  • Sustained virological response

Drug/Treatment

  • Hydroxyurea

  • KRT-232

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • NCT03662126

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved